These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

A new study reveals that Pfizer’s COVID-19 vaccine may cause subtle but measurable changes in the eyes — specifically in the ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

A new study has linked a type of injectable birth control with meningioma. The manufacturer says the claims are “without ...

A new study allegedly discovered that women using a specific form of birth control had a "significantly higher risk" of ...

Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget about forever.

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Dozens of alumni of a group the State Department has linked to espionage have secured jobs in sensitive industries.

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...